FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2539951857> ?p ?o ?g. }

• W2539951857 abstract "Abstract Aberrant DNA methylation of promoter-associated CpG islands is a mechanism of epigenetic silencing frequently encountered in human neoplasia. Hypermethylation of several genes such as p15INK4B, p16INK4A, progesterone receptor, and the retinoic acid receptor β have been detected in patients (pts) with advanced-stage MF. Azacitidine (Vidaza™) is a hypomethylating agent that induces reactivation of methylated genes and has been approved for the treatment of pts with myelodysplastic syndromes. The objective of this phase II trial was to study the efficacy of azacitidine in pts with relapsed or refractory MF (primary, or secondary to essential thrombocythemia or polycythemia vera) or newly-diagnosed with a Lille risk score 1 or 2 (risk factor are white blood cell [WBC] count >30x109/L or <4x109/L, and hemoglobin [Hb] <10 g/dL). Azacitidine was given at 75 mg/m_ daily (dose level [DL] 0) for 7 days every 4 weeks for 6 cycles but this could be reduced to 50 (DL -1), 25 (DL -2), or 12.5 (DL -3) or increased to 100 (DL +1) mg/m_ according to toxicity or lack of response, respectively. Thirty-four pts have been treated, median age 66 years (range 39–82), time from MF diagnosis to azacitidine therapy 21 months (range 1–361), median Hb 10.3 g/dL (range 8.2–14.3), WBC 10.7x109/L (range 1.7–57.7), and platelets 205x109/L (range 11–1216). Pts had received a median of 1 prior therapy (range 0–6), including hydroxyurea (HU; n=16), anagrelide (AG; n=8), lenalidomide (n=6), thalidomide (n=6), etanercept (n=2), and pegylated interferon (n=2). Six pts had not received any prior therapy. The JAK2 V617F mutation was detected in 19 (70%) of 27 tested pts and 12 of 34 (35%) had abnormal cytogenetics. A total of 142 cycles have been administered. All 34 patients are evaluable for response and toxicity. Responses have been observed in 10 (29%) pts so far, including complete response (CR) in 1 (normal blood counts and <5% bone marrow blasts; off HU, AG, growth factors, and no transfusions), partial response (PR) in 7 (defined as at least 2 of the following: Hb increase by ≥2 g/dL, 50% increase in platelets, decrease of bone marrow blasts or organomegaly by ≥50%, normalization of WBC count without blasts, or reduction in bone marrow fibrosis), and hematologic improvement (HI) in 2 (defined as at least 2 of the following: decrease by ≥25% of pretreatment leukocytosis, splenomegaly, or marrow blasts, or increase of Hb by ≥1g/dl or platelets by ≥25%). The median time to best response was 7.5 weeks (range, 3 to 26). Fifteen (44%) pts discontinued azacitidine due to: lack of response in 7, transformation to acute myeloid leukemia in 2, death (unrelated to azacitidine therapy) in 1, pt’s decision in 1, grade 3–4 toxicity in 2, and other medical reasons in 2. Azacitidine has been generally well tolerated; 10 pts (29%) had grade 3 or 4 toxicity; neutropenia was the only grade 4 toxicity (in 4 pts). Eleven pts (32%) have required dose reduction to DL -1, of which 3 reduced to DL -2, and 9 pts (26%) escalated the dose to DL +1. In summary, azacitidine is well tolerated and has activity in a subset of pts with MF, with current overall response rate of 29%. Updated clinical results will be presented." @default.
• W2539951857 created "2016-11-04" @default.
• W2539951857 creator A5015101485 @default.
• W2539951857 creator A5016607292 @default.
• W2539951857 creator A5019337932 @default.
• W2539951857 creator A5038307470 @default.
• W2539951857 creator A5057106377 @default.
• W2539951857 creator A5061026876 @default.
• W2539951857 creator A5061285204 @default.
• W2539951857 creator A5061542974 @default.
• W2539951857 creator A5063761513 @default.
• W2539951857 creator A5085521139 @default.
• W2539951857 date "2006-11-16" @default.
• W2539951857 modified "2023-10-15" @default.
• W2539951857 title "A Phase II Study of Azacitidine (Vidaza™) for Patients with Myelofibrosis (MF)." @default.
• W2539951857 doi "https://doi.org/10.1182/blood.v108.11.2706.2706" @default.
• W2539951857 hasPublicationYear "2006" @default.
• W2539951857 type Work @default.
• W2539951857 sameAs 2539951857 @default.
• W2539951857 citedByCount "1" @default.
• W2539951857 crossrefType "journal-article" @default.
• W2539951857 hasAuthorship W2539951857A5015101485 @default.
• W2539951857 hasAuthorship W2539951857A5016607292 @default.
• W2539951857 hasAuthorship W2539951857A5019337932 @default.
• W2539951857 hasAuthorship W2539951857A5038307470 @default.
• W2539951857 hasAuthorship W2539951857A5057106377 @default.
• W2539951857 hasAuthorship W2539951857A5061026876 @default.
• W2539951857 hasAuthorship W2539951857A5061285204 @default.
• W2539951857 hasAuthorship W2539951857A5061542974 @default.
• W2539951857 hasAuthorship W2539951857A5063761513 @default.
• W2539951857 hasAuthorship W2539951857A5085521139 @default.
• W2539951857 hasConcept C104317684 @default.
• W2539951857 hasConcept C126322002 @default.
• W2539951857 hasConcept C143998085 @default.
• W2539951857 hasConcept C150194340 @default.
• W2539951857 hasConcept C190727270 @default.
• W2539951857 hasConcept C2776012956 @default.
• W2539951857 hasConcept C2776239401 @default.
• W2539951857 hasConcept C2778488018 @default.
• W2539951857 hasConcept C2778837598 @default.
• W2539951857 hasConcept C2780007613 @default.
• W2539951857 hasConcept C2780076729 @default.
• W2539951857 hasConcept C2780817109 @default.
• W2539951857 hasConcept C2781057849 @default.
• W2539951857 hasConcept C31760486 @default.
• W2539951857 hasConcept C502942594 @default.
• W2539951857 hasConcept C535046627 @default.
• W2539951857 hasConcept C54355233 @default.
• W2539951857 hasConcept C71924100 @default.
• W2539951857 hasConcept C86803240 @default.
• W2539951857 hasConceptScore W2539951857C104317684 @default.
• W2539951857 hasConceptScore W2539951857C126322002 @default.
• W2539951857 hasConceptScore W2539951857C143998085 @default.
• W2539951857 hasConceptScore W2539951857C150194340 @default.
• W2539951857 hasConceptScore W2539951857C190727270 @default.
• W2539951857 hasConceptScore W2539951857C2776012956 @default.
• W2539951857 hasConceptScore W2539951857C2776239401 @default.
• W2539951857 hasConceptScore W2539951857C2778488018 @default.
• W2539951857 hasConceptScore W2539951857C2778837598 @default.
• W2539951857 hasConceptScore W2539951857C2780007613 @default.
• W2539951857 hasConceptScore W2539951857C2780076729 @default.
• W2539951857 hasConceptScore W2539951857C2780817109 @default.
• W2539951857 hasConceptScore W2539951857C2781057849 @default.
• W2539951857 hasConceptScore W2539951857C31760486 @default.
• W2539951857 hasConceptScore W2539951857C502942594 @default.
• W2539951857 hasConceptScore W2539951857C535046627 @default.
• W2539951857 hasConceptScore W2539951857C54355233 @default.
• W2539951857 hasConceptScore W2539951857C71924100 @default.
• W2539951857 hasConceptScore W2539951857C86803240 @default.
• W2539951857 hasLocation W25399518571 @default.
• W2539951857 hasOpenAccess W2539951857 @default.
• W2539951857 hasPrimaryLocation W25399518571 @default.
• W2539951857 hasRelatedWork W1984010596 @default.
• W2539951857 hasRelatedWork W1989167457 @default.
• W2539951857 hasRelatedWork W2029529782 @default.
• W2539951857 hasRelatedWork W2539951857 @default.
• W2539951857 hasRelatedWork W2557422108 @default.
• W2539951857 hasRelatedWork W2571330258 @default.
• W2539951857 hasRelatedWork W2577949479 @default.
• W2539951857 hasRelatedWork W2594981444 @default.
• W2539951857 hasRelatedWork W2903749170 @default.
• W2539951857 hasRelatedWork W3213898481 @default.
• W2539951857 isParatext "false" @default.
• W2539951857 isRetracted "false" @default.
• W2539951857 magId "2539951857" @default.
• W2539951857 workType "article" @default.